TP53-mutated ALL: hyper-CVAD negates effect of mutation on outcomes

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Patients with adult B-cell immunophenotype acute lymphoblastic leukemia (ALL) and tumor protein 53 (TP53) mutations have poor prognosis; treatment with hyper-CVAD-based (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimens appears to overcome the prognostic effe...